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The association of thromboembolic events and
malignant disease is well established. Otherwise
healthy patients who have an initial episode of idio-
pathic venous thromboembolism have approximate-
ly a 10% incidence rate of harboring cancer.1-4 In
patients with recurrent idiopathic deep venous
thrombosis (DVT), this risk is even higher (17.1%).2
Monreal et al5 reported a similar association with
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Purpose: It has been proposed that inferior vena cava filter placement should be the ini-
tial treatment of deep venous thrombosis (DVT) or pulmonary embolus (PE) in patients
with coexisting malignant disease. We have chosen instead to selectively place filters only
in patients with either a contraindication to anticoagulation therapy or a subsequent
complication from anticoagulation therapy. The treatment efficacy and mortality rates in
patients with concomitant malignant disease and venous thromboembolism using this
approach was determined.
Methods: We retrospectively reviewed all patients at our institution with malignant dis-
ease in whom venous thromboembolism developed between August 1991 through
August 1996 and identified 166 patients with PE (n = 8), DVT (n = 147), and DVT/PE
(n = 11). Of these patients, 138 (83.1%) were initially treated with anticoagulation ther-
apy, and 28 (16.9%) had primary filter placement because of contraindications to anti-
coagulation therapy (10 for intracranial tumors, 11 for recent or upcoming operations,
6 for recent hemorrhage, and 1 for a malignant bloody pericardial effusion). 
Results: Thirty-two (23%) of the 138 patients who initially underwent anticoagulation
therapy subsequently required a filter for the following reasons: bleeding (n = 15,
10.9%); recurrent thromboembolism (n = 6, 4.3%); heparin-induced thrombocytopenia
(n = 1, 0.7%); and perceived high risk for bleeding with continued anticoagulation ther-
apy (n = 11, 8%). Both bleeding and recurrent thromboembolism developed in 1 patient.
Sixty patients (36%) received filters. No major technical complications occurred from fil-
ter placement. Major recurrent thromboembolic complications developed in 10 patients:
DVT (n = 6, 10%), PE (n = 2, 3.3%), inferior vena cava thrombosis and phlegmasia
cerulea dolens (n = 1, 1.7%), superior vena cava thrombosis (n = 1, 1.7%). Venous gan-
grene developed in 1 patient with DVT. The 1-year actuarial survival rates for patients
treated with filter and anticoagulation therapy were 35% and 38%, respectively (P = NS).
Conclusion: In summary, our experience suggests that 64% of patients with malignant
disease and venous thromboembolism are effectively treated with anticoagulation alone;
17% require primary filter placement for standard indications, and an additional 19%
require subsequent filter placement because of complications (primarily bleeding) or
failure of anticoagulation therapy. Although technical complications of filter placement
are low, serious life-threatening or limb-threatening thromboembolic complications
developed in 17% of patients. Survival was poor in all patients, regardless of treatment.
These data support a conservative approach of routine anticoagulation therapy with
selective filter placement. (J Vasc Surg 1998;28:800-7.)
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pulmonary embolus (PE); 22% of patients who had
an idiopathic PE were found to have a concomitant
malignant disease. In fact, in one report6 of 399
patients with PE, the most common cause of death
(34.7%) was cancer. Conversely, the second most
common cause of death in patients with malignant
disease is thromboembolism.4 In particular, adeno-
carcinoma of the pancreas, female reproductive
organs, breast, colon, lung, and prostate have been
found to be associated with the highest risk of
DVT.1 Although a consensus has not been reached,
many physicians recommend screening for occult
malignant disease when patients have a single
episode of idiopathic thromboembolism.1,3,4
Patients with malignant disease are at increased risk
for thromboembolic complications because of a rela-
tive hypercoagulable state. Investigators have demon-
strated that tumor cells can activate both thrombin
and fibrin by expression of tissue factor and produc-
tion of other substances, such as mucin and a cysteine
protease, which activates factor X.7 In addition, tumor
cells can interact with monocytes8 and platelets7 to
induce procoagulant activities. Paradoxically, others
have noted that patients with malignant disease are at
increased risk of hemorrhagic complications after ther-
apeutic anticoagulation therapy.10,11 Because of this
increased risk for both bleeding and thromboembolic
events, some have proposed that inferior vena cava
(IVC) filter placement, rather than anticoagulation
therapy, should be the initial treatment of throm-
boembolic events in patients with malignant dis-
ease.12,13. Our practice has been to selectively place fil-
ters in patients with either a contraindication to anti-
coagulation therapy or in whom a complication from
anticoagulation therapy subsequently develops. The
results of this treatment algorithm are reviewed, and
the current mortality rate of patients with combined
malignant disease and thromboembolism is reported.
METHODS 
We retrospectively reviewed the medical records
of all patients at the University of Arizona Health
Sciences Center with discharge International
Classification of Diseases, Ninth Revision codes for
malignant disease and venous thromboembolism
from August 1991 through August 1996 and iden-
tified 245 patients with both malignant disease and
venous thromboembolism. After reviewing all inpa-
tient charts in detail, 79 patients were excluded from
analysis because of either inaccurate coding or failure
to adequately support the diagnosis of the throm-
boembolic event. Most of the coding errors were
related to coding venous disorders, such as portal
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vein thrombosis, superficial thrombophlebitis, or
veno-occlusive disease in bone marrow transplant
patients, as DVT. In the remaining 166 patients,
DVT was verified by means of either duplex ultra-
sound scan or venography, and PE was diagnosed by
means of high probability ventilation/perfusion
(V/Q) scan or pulmonary arteriography. 
All the subsequent inpatient and outpatient hos-
pital charts were reviewed for potential hemorrhagic
or recurrent thromboembolic complications. Major
hemorrhage was defined as bleeding that was poten-
tially life threatening (eg, intracranial hemorrhage
(ICH), gastrointestinal hemorrhage needing trans-
fusion, or other hemorrhage causing a drop in
hemoglobin greater than 2g/dL), and minor bleed-
ing was defined as all other bleeding related to anti-
coagulation therapy. The diagnosis of recurrent
thromboembolism was made in the following
instances: development of a contralateral DVT seen
by means of duplex ultrasound scan; documented
extension of an ipsilateral DVT to involve more
proximal deep veins seen by means of duplex ultra-
sound scan; a new area of ventilation-perfusion mis-
match seen by means of V/Q scan; or a new PE seen
by means of pulmonary arteriography. Diagnostic
studies were pursued only for new or worsening
symptoms of thromboembolism.
Patient survival after the initial thromboembolic
event was recorded. When possible, patients or their
family members were contacted to inquire about
symptoms of recurrent thromboembolic events or
bleeding episodes. Additionally, the cancer registry
was reviewed to confirm follow-up data information
and patient survival. Patient survival was calculated
with life table analysis, with a P value less than .05
considered statistically significant. Statistical analysis
was performed with a computerized software pack-
age SPSS (version 7.5, SPSS, Inc, Chicago, Ill).
RESULTS
The study group consisted of 166 patients with a
mean age of 60 (range, 2 to 87 years). Included were
85 women and 81 men, 8 with PE, 147 with DVT,
and 11 with combined DVT/PE. DVT was local-
ized to the lower extremity in 120 patients, IVC (n
= 5), superior vena cava (n = 5), and upper extremi-
ty (n = 28). As initial treatment for their throm-
boembolic event, 138 (83%) patients underwent
anticoagulation therapy, and 28 (17%) underwent
primary filter placement for absolute or relative con-
traindications to anticoagulation therapy. These con-
traindications included 10 intracranial neoplasms, 11
recent or upcoming operations, 6 patients consid-
JOURNAL OF VASCULAR SURGERY
802 Ihnat et al November 1998
ered to be at high risk for hemorrhage (1 with active
peptic ulcer disease, 1 with anemia and a falling
hematocrit but no identified source of hemorrhage,
1 with thrombocytopenia, 2 with ulcerated tumors,
and 1 with a history of a lower gastrointestinal
bleed), and 1 for a bloody malignant pericardial
tamponade requiring catheter drainage.
Thirty-two (23%) of the 138 patients who ini-
tially underwent anticoagulation therapy subse-
quently required filter placement for 33 complica-
tions from anticoagulation therapy. These complica-
tions included 15 (10.9%) patients with bleeding (4
major, 11 minor), 6 (4.3%) with recurrent throm-
boembolism (1 PE, 4 DVT, 1 DVT/PE), 11 (8%)
with a perceived high risk for continued anticoagu-
lation therapy, and 1 (0.7%) with heparin-induced
thrombocytopenia. Both an ICH and a new DVT
developed in 1 patient. The 4 major hemorrhagic
complications included ICH in 2 patients, an upper
gastrointestinal bleed in 1 patient, and a gluteal
hemorrhage requiring a transfusion of 4 units 
in 1 patient. None of these patients died because 
of hemorrhage or recurrent thromboembolism.
Hemorrhagic complications developed in an addi-
tional 3 (2.2%) patients (2 major, 1 minor), but they
did not undergo filter placement. One of these
patients had an upper gastrointestinal hemorrhage
from esophagitis that spontaneously resolved, and
anticoagulation therapy was continued. ICH devel-
oped in the other 2 patients: 1 died of the ICH, the
other’s anticoagulation was reversed, but no filter
was placed. This patient died several days later of dis-
seminated lymphoma. One other patient with lung
cancer who underwent anticoagulation therapy died
of a respiratory arrest (no autopsy was performed).
Of the 18 patients in whom hemorrhagic complica-
tions developed because of anticoagulation therapy,
only 4 (22%) had supratherapeutic international nor-
malized ratio (INR) values. An association between
hemorrhage and increasing age (P = .0478, odds
ratio [OR] = 1.044) was found by means of bivari-
ate logistic regression analysis. Thus, for every 5
years a patient aged, a hemorrhagic complication
was 1.24 times more likely to develop. Multivariate
logistic regression analysis failed to find any associa-
tion between hemorrhage and gender, stage, or
tumor type.
Sixty patients (36%) ultimately received filters, 2
of whom were also treated with low-dose Coumadin
3 days after filter insertion to treat the underlying
DVT, yet minimize the risk of precipitating a hem-
orrhagic event. All filters were placed percutaneous-
ly by the interventional radiology department; 2 fil-
ters were placed in the suprarenal IVC because of
IVC thrombus, the remainder were placed in the
infrarenal IVC. The filter types were as follows:
Greenfield (N = 34), Venatech (N = 18), Nitinol (N
= 5), and Birdsnest (N = 2). Patients with primary
central nervous system (CNS) malignant disease
were more likely to receive filters (Table I). Small
groin hematomas developed in 2 patients; no other
technical complications occurred from filter place-
ment. Major recurrent thromboembolic complica-
tions developed in 10 (17%) patients: 6 (10%) DVT
(4 contralateral, 2 ipsilateral), 2 (3.3%) PE, 1 (1.7%)
SVC thrombosis, and 1 (1.7%) IVC thrombosis with
phlegmasia cerulea dolens. One of the 2 patients
with ipsilateral extension of DVT had venous gan-
grene 2 months after filter placement. 
Mean follow-up time was 13.1 months for the
patients who received IVC filters, compared with
10.6 months in the anticoagulated group. The 1-
year survival rate for the patients treated with IVC
filter was 35%, compared with 38% for those treated
with anticoagulation therapy (Fig 1). This difference
was not statistically significant (log rank). Extent of
tumor dissemination was similar in both groups
(Table II). As expected, patients with metastatic can-
cer exhibited a much poorer survival rate, 12.6% at
9 months (P < .001 [log-rank test]).
DISCUSSION 
When deciding which treatment modality to use
in patients with venous thromboembolism and con-
Table I. Histologic type and distribution of malig-
nant disease in patients with major thromboembolism
Anticoagulation Filter
Histology therapy(n = 138) (n = 60)
Hematopoietic 21 3
Gastrointestinal tract adenocarcinoma 18 6
Lung 16 6
Female reproductive organ 16 6
Breast 12 3
Bladder 8 8
Central nervous system 7 11
Pancreas 7 3
Prostate 7 4
Melanoma 5 4
Squamous cell 5 3
Sarcoma 4 3
Unknown primary (adeno) 4 0
Renal cell 2 0
Germ cell 2 0
Cholangiocarcinoma 1 0
Gall bladder 1 0
Bone (unspecified) 1 0
Carcinoid 1 0
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current malignant disease, the risks of hemorrhagic
complications must be weighed against the risk of
recurrent thromboembolic events. The reported risk
of hemorrhagic complications in patients with can-
cer who undergo anticoagulation therapy is highly
variable. Gritter et al10 demonstrated a 12% inci-
dence rate of major and minor hemorrhagic compli-
cations at 12 months in 53 patients with malignant
disease (a 4-fold increase over 208 patients without
malignant disease). A large proportion of these
patients were excessively anticoagulated, with a
mean INR of 4.2 in those who had hemorrhagic
complications. Krauth et al11 similarly noted a high-
er incidence rate of major and minor hemorrhagic
complications in patients with malignant disease:
1.6% and 4.8%, respectively, per patient per month.
All these complications occurred in patients with a
supratherapeutic INR. Cohen et al12 studied 11
patients with malignant disease and thromboem-
bolism and noted a 27% incidence of hemorrhage;
Calligaro et al13 noted a 35% incidence rate of hem-
orrhage in 20 patients with stage III and IV malig-
nant disease and DVT or PE. Both Cohen and
Calligaro concluded that IVC filter should be the
primary treatment method of thromboembolism in
patients with malignant disease. Moore et al14
reported a 50% incidence rate of hemorrhage in 32
patients with malignant disease and thromboem-
bolism. This latter series had a much higher rate of
hemorrhage than other series, and it predated the
use of standardized INR (Table III). In our series,
only 22% of patients in whom hemorrhagic compli-
cations developed had supratherapeutic INR values;
meticulous control of anticoagulation therapy may
partly explain our low rate of hemorrhagic events.
The risk of ICH is of particular concern in
patients with primary or metastatic CNS neoplasms,
especially in those with melanoma, choriocarcinoma,
and renal cell carcinoma. Although a perception
exists among some physicians that CNS neoplasms
constitute a prohibitive risk for anticoagulation ther-
apy, Schiff et al15 reviewed the records of 52 patients
with brain metastasis and thromboembolic disease
and concluded that anticoagulation therapy was
acceptably safe in most patients. Of the 42 patients
treated with anticoagulation therapy, bleeding com-
plications developed in 19%, including 7% with
major CNS bleeding (2 patients died). Two thirds of
these patients were excessively anticoagulated. Levin
et al16 and Olin et al17 reported a 0% and 4% inci-
dence of intracranial hemorrhage in 15 and 25
patients, respectively, with CNS malignant disease
and thromboembolism; both studies concluded that
anticoagulation therapy was safe and efficacious as a
primary treatment of thromboembolism in patients
with CNS malignant disease.
The reported risk of recurrent thromboembolic
events in patients with malignant disease is also high-
ly variable, but is clearly higher than the risk in
patients without malignant disease. Gritter et al10
noted a 3.5-fold increase in the risk of any throm-
boembolic event in patients with malignant disease
who underwent anticoagulation therapy. In the
largest series of patients with malignant disease who
had IVC filters placed, Greenfield et al18 noted a
30.7% incidence of DVT in 166 patients after filter
placement and a 1.8% incidence rate of recurrent
PE. These patients underwent an average of 4
duplex ultrasound scan examinations to monitor for
new thrombotic events, in contrast with other
reports that did not routinely survey patients. Thirty-
seven percent of these patients also underwent anti-
coagulation therapy simultaneously. Among the anti-
coagulated patients, a 15% incidence rate of either
hemorrhage or thrombocytopenia occurred, requir-
Fig 1. Life table survival.
Table II. Distribuion of tumor stage
Stage Anticoagulation (n = 138) Filter (n = 60)
Stage 0 1 1
Stage I 2 4
Stage II 19 5
Stage III 26 38
Stage IV 70 38
Unstaged 20 2
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ing cessation of the anticoagulation therapy. A con-
trol group treated primarily with anticoagulation
therapy alone was not reported.
In Schiff ’s series15 of 42 patients treated with
anticoagulation therapy, recurrent thromboem-
bolism developed in 12% of patients, compared with
40% of 10 patients treated with IVC filter alone. The
filter group had a 20% rate of PE. Levin et al16 and
Olin et al17 reported a 13% and 0% incidence rate 
of recurrent thromboembolism, respectively, in
patients who underwent anticoagulation therapy
with CNS malignant disease, compared with 62%
and 4% in patients treated with IVC filter placement.
These authors concluded that anticoagulation thera-
py was safe and more effective than filter placement
in treating thromboembolism. Conversely, Cohen et
al19 reported only a 4.8% incidence rate of recurrent
thromboembolism in 41 patients with IVC filters
and malignant disease, compared with a 9% inci-
dence rate in 11 historical controls treated with anti-
coagulation therapy.12 Most of these patients, how-
ever, were not tested with venography or duplex
scanning to identify recurrent DVT despite exacer-
bations in limb edema. Calligaro et al13 reported a
15% incidence rate of recurrent thromboembolism
in 20 patients with stage III and IV cancers who
were primarily treated with IVC filter, compared
with 30% in patients treated with anticoagulation
therapy (Table IV). Of the 6 patients who under-
went anticoagulation therapy in our series in whom
recurrent thromboembolism developed, only 2
(33%) had subtherapeutic INR values (a simultane-
ous ICH developed in 1; the other had been off
Coumadin for 1 week). Data regarding the antico-
agulation status of patients with recurrent throm-
boembolic events in most other series is not avail-
able, but careful monitoring of anticoagulation ther-
apy may partly explain our low rate of recurrent
thromboembolism. 
Overall, a higher rate of hemorrhagic complica-
tions exists in patients with malignant disease and
venous thromboembolism when treated with antico-
agulation therapy instead of with vena cava filter
placement. Conversely, a higher frequency of throm-
boembolic complications occurs in those treated
with vena cava filter placement. Our retrospective
review revealed an overall 13% incidence rate of
hemorrhagic complications (4.3% major, 8.7%
Table IV. Literature review of patients with malignant disease and thromboembolism treated with inferior
vena cava filter placement
Number Mean follow-up
Authors (year) of patients period Bleed DVT/PE (PE) Notes
Olin et al17 (1987) 24 0% 4.2% (4.2%) Central nervous system neoplasms
Calligaro et al13 (1991) 20 10 months 0% 15% (0%) Stage III/IV neoplasms
Cohen et al19 (1992) 41 6.4 months 0% 4.8% (2.4%)
Levin et al16 (1993) 42 3 months 0% 62% (11.9%) Central nervous system neoplasms
Schiff et al15 (1994) 10 < 1 month 0% 40% (20%) Brain metastasis
Greenfield et al18 (1997) 166 10 months – 32.5% (1.8%) 37% anticoagulated
Ihnat et al (1998) 60 12 months 0% 17% (3.3%)
Total 363 0% 28% (4%)
DVT, deep venous thrombosis; PE, pulmonary embolus.
Table III. Literature review of patients with malignant disease and thromboembolism treated with antico-
agulation therapy
Number
Authors (year) of patients Study duration Bleed DVT/PE (PE) Notes
Moore et al14 (1981) 32 3 months 50% 19% (19%)
Olin et al17 (1987) 25 3 months 8% 0% (0%) Central nervous system neoplasms
Calligaro et al13 (1991) 20 not reported 35% 30% (10%) Stage III/IV neoplasms
Cohen et al12 (1991) 11 not reported 27% 9% (9%)
Levin et al16 (1993) 15 not reported 0% 13% (7%) Central nervous system neoplasms
Schiff et al15 (1994) 42 3.3 months 19% 12% (5%) Brain metastasis
Gritter et al10 (1995) 53 12 months 12%
Ihnat et al (1998) 138 13% 4.3% (1%)
Total 336 19% 7.4% (5%)
DVT, deep venous thrombosis; PE, pulmonary embolus.
minor) in patients who underwent anticoagulation
therapy with combined malignant disease and
thromboembolism. The incidence rate of recurrent
thromboembolic events for the patients who under-
went anticoagulation therapy was 4.3%, compared
with 17% in patients treated with IVC filter place-
ment. This reflects an inability of the IVC filter to
prevent recurrent DVT, despite its proven efficacy in
preventing PE. In a recent prospective trial of 400
patients with DVT, all patients underwent anticoag-
ulation therapy for 3 months, and half were ran-
domized to receive IVC filters. A statistically signifi-
cant higher incidence rate of recurrent DVT was
noted in the filter group at 2 years, 20.8% versus
11.6%.20 Sarasin et al21 performed a meta-analysis of
the literature and concluded that both vena cava fil-
ter placement and anticoagulation therapy yielded
similar results in patients with malignant disease and
thromboembolism, but vena cava filter placement
was less expensive and provided a greater gain in
quality-adjusted life expectancy when anticoagula-
tion therapy monitoring was taken into consideration.
With the current use of outpatient low–molecular-
weight heparin treatments of thromboembolism,
this possible benefit may be moot. 
Because none of the patients in our series were
treated simultaneously with both IVC filter and anti-
coagulation therapy, conclusions regarding com-
bined therapy cannot be drawn from this series.
Only 2 patients were treated with low-dose
Coumadin (1 or 2 mg/day) and IVC filter place-
ment. Neither of these patients had a subsequent
hemorrhagic or recurrent thromboembolic event,
but the number is too small to formulate conclu-
sions. Certainly, both treatment methods are not
mutually exclusive, and some patients at high risk for
death from subsequent PE may benefit from com-
bined treatment. This subject needs further study.
In addition to weighing the risks of hemorrhagic
complications versus recurrent thromboembolism,
patient survival must be considered. Some investiga-
tors have cautioned against aggressive treatment of
patients with advanced staged malignant disease.
Rosen et al22 noted that 16 of 61 patients (26%) with
malignant disease died within 3 weeks of filter place-
ment. Magnant et al23 reported 19% of patients died
of disseminated cancer during the same hospitalization
as the filter placement. Walsh et al24 noted 24% of
patients with malignant disease who underwent filter
placement for prophylaxis against thromboembolism
had died within 2 months. These authors discouraged
filter placement in patients with poor prognoses, in
whom a survival benefit is unlikely. The 3-month mor-
tality rate in our series was 38% and 42%, respectively,
for patients who underwent anticoagulation therapy
versus the filter group.
Among the patients with lower extremity DVT,
only 1 patient had thrombus limited to the calf
veins, and 6 patients had thrombus limited to the
popliteal veins. The remainder of the patients with
lower-extremity DVT had femoral or iliofemoral
DVT. Because of the small numbers of patients with
thrombus limited to the calf or popliteal veins, con-
clusions regarding relationships between site of
thrombosis and outcome cannot be drawn. Among
the 28 patients with upper-extremity DVT, hemor-
rhagic complications developed in 2 patients (7.1%)
(1 major, 1 minor), and no recurrent thromboem-
bolic events developed; all were treated with antico-
agulation therapy. Although patients with upper
extremity DVT are not usually treated with vena
cava filter placement, they are at risk for PE and
recurrent thrombotic events. A study by Prandoni et
al25 examined 27 patients with upper extremity
DVT and found a 36% incidence rate of PE at the
time of diagnosis; two thirds of these patients were
asymptomatic. These patients were treated with anti-
coagulation therapy for at least 3 months and subse-
quently were studied for 1 to 4 years. Recurrent
upper extremity DVT developed in 2 of these
patients; 1 died of a massive PE. A new lower
extremity DVT developed in another patient during
the follow-up period. Prandoni concluded that upper
extremity DVT is a different manifestation of the
same disease compared with lower extremity DVT.
Several prospective studies by Monreal et al26,27 have
also noted a significant incidence rate of asympto-
matic PE in patients with catheter-related upper
extremity DVT. Because these patients are at signifi-
cant risk for recurrent thromboembolic events, we
feel their inclusion is appropriate.
In our series, 18 (30%) of the indications for fil-
ter placement were relative indications, and the
patients probably could have been safely anticoagu-
lated. In the primary filter group, 5 patients who
had CNS malignant disease were not undergoing
radiation therapy and did not have CNS neoplasms,
such as melanoma, choriocarcinoma, or renal cell
carcinoma, considered to be high risk for ICH.
Seven patients had primary filter placement for
recent or upcoming surgery other than neuro-
surgery; these procedures could have been per-
formed through a heparin window. Similarly, some
of the patients initially tolerating anticoagulation
therapy underwent filter placement for a perceived
risk of subsequent hemorrhage and likely could
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have safely continued to undergo anticoagulation
therapy. This group included 3 patients with
upcoming non-neurosurgical operations, 2 others
considered high-risk, but not by any standard crite-
ria, and 1 in whom concern for the risk of clot prop-
agation led to filter placement. 
The present study is subject to a number of limi-
tations. First, it is retrospective and nonrandomized,
and selection bias may exist between the 2 treatment
groups. Certainly, a higher proportion of bladder and
CNS tumors comprised the filter group, and the
Coumadin group included a higher proportion of
patients with hematopoietic malignant disease. The
significance of this difference is unknown, however,
because the histologic types associated with the high-
est risk of hemorrhagic complications maintained a
similar distribution between the 2 groups. Another
potential limitation of our study is the possibility of
additional coding errors. Patients who received a
diagnosis and treatment of DVT that was not coded
as a DVT would not have been included in our series
and could alter the results. Third, the potential for
undiagnosed thromboembolic events exists, because
our rate of recurrent thromboembolic events in both
groups was lower than those reported in the litera-
ture. Because of the retrospective nature of this
study, the lack of routine duplex scan screening for
recurrent DVT, and the possibility that recurrent
thromboembolic events were treated at outside facil-
ities, we may have underestimated the recurrent
thromboembolic event rate in both groups.
CONCLUSIONS 
Overall, our experience suggests that most patients
with combined malignant disease and venous throm-
boembolism can be effectively treated with anticoagu-
lation therapy alone; 17% require primary filter place-
ment for standard indications, and an additional 19%
require subsequent filter placement because of com-
plications of anticoagulation therapy. Although tech-
nical complications of filter placement are low, serious
life-threatening or limb-threatening thromboembolic
complications develop in 17% of patients treated with
filter, compared with 8.6% of patients who underwent
anticoagulation therapy. Survival was equally poor in
both groups, regardless of treatment. Our series was
too small to determine if subgroups, such as patients
with poor pulmonary reserve, exist in which combined
filter and anticoagulation therapy would confer sur-
vival benefit. These data support anticoagulation ther-
apy as a safe and effective primary treatment method
in patients with venous thromboembolism and malig-
nant disease, reserving IVC filter placement for
patients with either contraindications or complications
from anticoagulation therapy.
We thank Monica Kester, MS, for her assistance with
the statistical analysis.
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